person · Reporting owner
Gallagher Patrick Stephen
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Faeth Therapeutics, Inc.
Report date February 15, 2023 · Filed September 11, 2023
Section 16 reporting ended · disclosed 2023-09-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,130 |
Reported balance
After 2023-02-15 transaction · row 1
1 source rowRow 1 · 2023-02-15 · Tax withholding · Disposed 9,383 · Balance 34,130 F1: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2023 Filed Feb 17, 2023 22:01 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-23-010734 · doc4.xml · derivative · entry 3 Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2023-02-14 F3 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:01 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 14,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010734 · doc4.xml · nonDerivative · entry 2 Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,515 F2 · shares: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:01 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 29,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010734 · doc4.xml · nonDerivative · entry 1 Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,313 F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested. Read SEC document |
| February 15, 2023 Filed Mar 29, 2023 21:13 UTC Amendment | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-23-021540 · doc4a.xml · derivative · entry 3 Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2023-02-14 F4 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| February 15, 2023 Filed Mar 29, 2023 21:13 UTC Amendment | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 14,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021540 · doc4a.xml · nonDerivative · entry 2 Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,513 F3 · shares: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date. F1 · balance_after: This amendment is being filed solely to correct the number of shares beneficially owned, which the original filing overreported by two shares. Read SEC document |
| February 15, 2023 Filed Mar 29, 2023 21:13 UTC Amendment | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 29,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021540 · doc4a.xml · nonDerivative · entry 1 Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,313 F1 · security: This amendment is being filed solely to correct the number of shares beneficially owned, which the original filing overreported by two shares. F2 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested. Read SEC document |
| February 15, 2023 Filed Sep 11, 2023 21:34 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | Tax withholdingCommon Stock | 9,383 | $1.50 | $14,074.50 |
DisclosureSEC source: 0001209191-23-048968 · doc4.xml · nonDerivative · entry 1 Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,130 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:20 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001209191-22-034040 · doc4.xml · derivative · entry 1 Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-05-31 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable as to 25% of the shares underlying the option on June 1, 2023, and the remaining 75% of the shares underlying the Option shall vest and become exercisable in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.